Optimistic That Legalization 2.0 Will Transform Canadian Cannabis Companies
David Kideckel is a Managing Director and Senior Equity Research Analyst at AltaCorp Capital Inc., heading the firm’s life sciences research franchise. Prior to joining AltaCorp Capital, Dr. Kideckel was at another leading independent investment dealer, in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. Dr. Kideckel is a seasoned industry executive, having spent nearly 15 years in international pharmaceutical, biotechnology and medical device companies where he held executive roles in sales, marketing, medical affairs and international business development. Dr. Kideckel holds a Ph.D. and MBA from the University of Toronto’s Institute of Medical Science and Rotman School of Management, respectively. He is a university Gold Medalist and a recipient of the Canadian Institutes of Health Research Science to Business Award. Profile
Word count: 3,337
TWST: Can you just tell the audience what your coverage is?
Dr. Kideckel: My coverage universe includes, within cannabis and life sciences,